We read with interest the recent reports1,2 describing the development of minimal change disease (MCD) following the first injection of the BNT162b2 vaccine (Pfizer-BioNTech) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).3 Here, we report a case of nephrotic syndrome relapse in a patient with known MCD following the first injection of the Pfizer-BioNTech coronavirus 19 (COVID-19) vaccine.